Pharmaceutical firm Cipla has launched a generic
version of Pirfenidone, a drug used against a form of chronic progressive lung
disease, in India.
The company has launched its generic drug under the brand Pirfenex, for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
The launch of Pirfenex is a significant step forward. With increased availability and affordability, Pirfenex could now offer hope to those afflicted with this condition.
Pirfenex will be manufactured at Cipla's manufacturing facility at Himachal Pradesh, which is approved by WHO, MCC-South Africa and TGA-Australia.
InterMune Inc had bought patent and intellectual property rights of Pirfenidone from Marnac, Inc and KDL GmbH in 2007.
The company has launched its generic drug under the brand Pirfenex, for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
The launch of Pirfenex is a significant step forward. With increased availability and affordability, Pirfenex could now offer hope to those afflicted with this condition.
Pirfenex will be manufactured at Cipla's manufacturing facility at Himachal Pradesh, which is approved by WHO, MCC-South Africa and TGA-Australia.
InterMune Inc had bought patent and intellectual property rights of Pirfenidone from Marnac, Inc and KDL GmbH in 2007.
No comments:
Post a Comment